Internal Medicine, Geriatrics, and Hepatology Unit, University Campus Bio-Medico, Rome, Italy.
Laboratory of Pathology of The National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy.
Can J Gastroenterol Hepatol. 2018 Mar 14;2018:7564835. doi: 10.1155/2018/7564835. eCollection 2018.
BACKGROUND & AIMS: Identifying NAFLD patients at risk of progression is crucial to orient medical care and resources. We aimed to verify if the effects determined by different single nucleotide polymorphisms (SNPs) could add up to multiply the risk of NAFLD and NASH-cirrhosis.
Three study populations, that is, patients diagnosed with NASH-cirrhosis or with noncirrhotic NAFLD and healthy controls, were enrolled. PNPLA3 rs738409, TM6SF2 rs58542926, KLF6 rs3750861, SOD2 rs4880, and LPIN1 rs13412852 were genotyped.
One hundred and seven NASH-cirrhotics, 93 noncirrhotic NAFLD, and 90 controls were enrolled. At least one difference in allele frequency between groups was significant, or nearly significant, for the PNPLA3, TM6SF2, and KLF6 variants ( < 0.001, < 0.05, and = 0.06, resp.), and a risk score based on these SNPs was generated. No differences were observed for SOD2 and LPIN1 SNPs. When compared to a score of 0, a score of 1-2 quadrupled, and a score of 3-4 increased 20-fold the risk of noncirrhotic NAFLD; a score of 3-4 quadrupled the risk of NASH-cirrhosis.
The effects determined by disease-associated variants at different can add up to multiply the risk of NAFLD and NASH-cirrhosis. Combining different disease-associated variants may represent the way for genetics to keep strength in NAFLD diagnostics.
识别有进展风险的非酒精性脂肪性肝病(NAFLD)患者对指导医疗保健和资源利用至关重要。我们旨在验证不同单核苷酸多态性(SNP)所决定的影响是否可以累加,从而增加 NAFLD 和非酒精性脂肪性肝炎(NASH)-肝硬化的风险。
共纳入了三组研究人群,即诊断为 NASH 肝硬化或非肝硬化性 NAFLD 以及健康对照者。对 PNPLA3 rs738409、TM6SF2 rs58542926、KLF6 rs3750861、SOD2 rs4880 和 LPIN1 rs13412852 进行基因分型。
共纳入了 107 例 NASH 肝硬化患者、93 例非肝硬化性 NAFLD 患者和 90 例健康对照者。在组间比较中,PNPLA3、TM6SF2 和 KLF6 变异体的等位基因频率存在差异,或差异具有统计学意义(<0.001、<0.05 和 =0.06),并且生成了基于这些 SNP 的风险评分。SOD2 和 LPIN1 SNP 未观察到差异。与评分 0 相比,评分 1-2 使非肝硬化性 NAFLD 的风险增加了 4 倍,评分 3-4 使风险增加了 20 倍;评分 3-4 使 NASH 肝硬化的风险增加了 4 倍。
不同疾病相关变异所决定的影响可以累加,从而增加 NAFLD 和 NASH 肝硬化的风险。联合不同疾病相关变异可能代表着遗传学在 NAFLD 诊断中的应用方向。